Price (delayed)
$2.3
Market cap
$244.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.4
Enterprise value
$239.97M
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to
There are no recent dividends present for MXCT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.